Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2009

View Archived Issues

New PI3K inhibitors imparted in recent UCB patent

Roche researchers discover novel GABA-A alpha5 receptor ligands

Recent Roche patents divulge new trace amine receptor 1 ligands

Novel thrombin inhibitors discovered by AstraZeneca researchers

Novel 11beta-HSD1 inhibitors imparted by Taisho for type 2 diabetes

Schering-Plough reflects on Q4 developments

NanoBio develops novel nanoemulsion antimicrobial for cystic fibrosis-related pathogens

Roche divulges new chemokine CCR2 antagonists for cardiovascular disorders

MAGL inhibition may be useful in treating behavioral disorders

MediciNova reaffirms proposal to acquire Avigen

Genentech collaborates with National Cancer Institute on GDC-0449

EntreMed presents initial preclinical and phase I results for ENMD-2076

ViroPharma reports phase III maribavir trial results in bone marrow transplant

MCT1 inhibition blocks hypoxic-oxygenated tumor cell symbiosis and leads to cell death

Inhibitex completes phase I trials of FV-100 and selects HCV compounds for development

Coated magnetic beads capture infectious human influenza viruses

Lundbeck to acquire Ovation

NanoViricides presents update on development of nanoviricide against HSV and adenovirus

AstraZeneca licenses TRI compounds discovered by Mayo Clinic and Virginia Tech

Ligand earns milestone from Schering-Plough on progress of BACE drug for AD

Critical Outcome Technologies reports results from in vitro studies of oncology drug COTI-2

Roche commences tender offer to Genentech

Xoma and Takeda expand antibody technology collaboration

Priligy receives first regulatory approvals for premature ejaculation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...